Devalingam Mahalingam

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. doi request reprint Targeting the mTOR pathway using deforolimus in cancer therapy
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Research and Therapy Center, University of Texas Health Science Centre San Antonio, TX, USA
    Future Oncol 5:291-303. 2009
  2. ncbi request reprint Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Cancer Chemother Pharmacol 74:77-84. 2014
  3. ncbi request reprint Targeting TRAIL towards the clinic
    Devalingam Mahalingam
    Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Curr Drug Targets 12:2079-90. 2011
  4. doi request reprint Emerging drugs in the treatment of pancreatic cancer
    Devalingam Mahalingam
    Institute of Drug Development, Division of Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Expert Opin Emerg Drugs 14:311-28. 2009
  5. pmc Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
    Jennifer S Carew
    Department of Medicine, Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, Texas 78245, USA
    J Biol Chem 286:6602-13. 2011
  6. pmc Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
    Jennifer S Carew
    Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX 78245, USA
    J Cell Mol Med 14:2448-59. 2010
  7. doi request reprint The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
    Kevin R Kelly
    Department of Medicine, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA
    J Cell Mol Med 15:2057-70. 2011
  8. ncbi request reprint Targeting aurora kinases in cancer treatment
    Kevin R Kelly
    The Institute for Drug Development, CTRC at University of Texas Health Science Center, 14960 Omicron Drive, San Antonio, TX 78245, USA
    Curr Drug Targets 12:2067-78. 2011
  9. doi request reprint Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
    Ronan T Swords
    Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA
    Blood 115:3796-800. 2010
  10. ncbi request reprint The Pim kinases: new targets for drug development
    Ronan Swords
    Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Curr Drug Targets 12:2059-66. 2011

Collaborators

Detail Information

Publications24

  1. doi request reprint Targeting the mTOR pathway using deforolimus in cancer therapy
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Research and Therapy Center, University of Texas Health Science Centre San Antonio, TX, USA
    Future Oncol 5:291-303. 2009
    ....
  2. ncbi request reprint Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Cancer Chemother Pharmacol 74:77-84. 2014
    ..Melanomas are vascular tumors with a high incidence of BRAF mutations driving tumor proliferation. Complete inhibition of vascular endothelial growth factor (VEGF) signaling has potential for enhanced antitumor efficacy...
  3. ncbi request reprint Targeting TRAIL towards the clinic
    Devalingam Mahalingam
    Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Curr Drug Targets 12:2079-90. 2011
    ..Finally, the progress of TRAIL and DR4/DR5-specific agonistic antibodies in clinical trials and the development of new receptor-selective TRAIL variants are discussed including future directions for apoptosis inducing therapy...
  4. doi request reprint Emerging drugs in the treatment of pancreatic cancer
    Devalingam Mahalingam
    Institute of Drug Development, Division of Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Expert Opin Emerg Drugs 14:311-28. 2009
    ..This failure may stem from the heterogeneous molecular pathogenesis of pancreatic cancers, which involves several oncogenic pathways and defined genetic mutations...
  5. pmc Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
    Jennifer S Carew
    Department of Medicine, Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, Texas 78245, USA
    J Biol Chem 286:6602-13. 2011
    ..Collectively, our results demonstrate that lucanthone is a novel autophagic inhibitor that induces apoptosis via cathepsin D accumulation and enhances vorinostat-mediated cell death in breast cancer models...
  6. pmc Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
    Jennifer S Carew
    Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX 78245, USA
    J Cell Mol Med 14:2448-59. 2010
    ..Collectively, our results establish that inhibition of autophagy with CQ induces ubiquitinated protein accumulation and VOR potentiates CQ-mediated aggregate formation, superoxide generation and apoptosis...
  7. doi request reprint The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
    Kevin R Kelly
    Department of Medicine, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA
    J Cell Mol Med 15:2057-70. 2011
    ..Our collective data demonstrate that this combination strategy represents a novel therapeutic approach for refractory CML that has the potential to suppress the emergence of T315I mutated CML clones...
  8. ncbi request reprint Targeting aurora kinases in cancer treatment
    Kevin R Kelly
    The Institute for Drug Development, CTRC at University of Texas Health Science Center, 14960 Omicron Drive, San Antonio, TX 78245, USA
    Curr Drug Targets 12:2067-78. 2011
    ..We will focus on recent preclinical and clinical studies that have explored the mechanism of action and clinical effect of Aurora inhibitors in cancer treatment...
  9. doi request reprint Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
    Ronan T Swords
    Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA
    Blood 115:3796-800. 2010
    ..Our findings indicate that MLN4924 is a highly promising novel agent that has advanced into clinical trials for the treatment of AML...
  10. ncbi request reprint The Pim kinases: new targets for drug development
    Ronan Swords
    Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Curr Drug Targets 12:2059-66. 2011
    ..As such, the Pim kinases are a very attractive target for pharmacological inhibition in cancer therapy. Novel small molecule inhibitors of the human Pim kinases have been designed and are currently undergoing preclinical evaluation...
  11. ncbi request reprint Targeting sarcomas: novel biological agents and future perspectives
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA
    Curr Drug Targets 10:937-49. 2009
    ....
  12. doi request reprint Cdc7 kinase - a new target for drug development
    Ronan Swords
    Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, USA
    Eur J Cancer 46:33-40. 2010
    ..In this review, we will address the current status of Cdc7 as an important target for new drug development...
  13. doi request reprint Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents
    Kevin Kelly
    Cancer Therapy and Research Center at the University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX 78229, USA
    Leuk Lymphoma 51:1399-413. 2010
    ..This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents...
  14. doi request reprint Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
    Yesid Alvarado
    Department of Hematology Oncology, Institute for Drug Development, The University of Texas Health Science Center San Antonio, TX 78229, USA
    Target Oncol 6:69-94. 2011
    ..This review focuses on a discussion of the pathway, its implications in cancer biology and results of clinical trials of rapalogs alone or in combination, organizing them by common malignancy type...
  15. doi request reprint The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents
    Kamalesh Sankhala
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX 78229, USA
    Target Oncol 4:135-42. 2009
    ..Pathogenesis of pneumonitis is uncertain, but various hypotheses have been suggested, including cell-mediated immune response to the drug...
  16. pmc Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Ronan Swords
    Institute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Drug Des Devel Ther 3:89-101. 2009
    ..The purpose of this review is to summarize the pre-clinical and clinical data on nilotinib in patients with CML who have failed prior therapy with IM or dasatinib...
  17. doi request reprint Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, Texas 78245, USA
    Clin Cancer Res 16:141-53. 2010
    ..Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus...
  18. doi request reprint Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
    Kevin Kelly
    Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX, USA
    Target Oncol 4:99-105. 2009
    ..The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures...
  19. ncbi request reprint Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer
    Pawel Osmulski
    Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas
    Prostate 74:1297-307. 2014
    ..Emerging evidence shows that nanomechanical phenotypes of circulating tumor cells (CTC) could become potential biomarkers for metastatic castration resistant prostate cancer (mCRPC)...
  20. doi request reprint A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy
    Ronan T Swords
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas, USA
    J Clin Pathol 64:809-13. 2011
    ..We compared a powered bone marrow aspiration and biopsy device to the traditional method by relatively assessing pain scores, procedure times, biopsy capture rates, quality of material retrieved, and safety and operator satisfaction...
  21. ncbi request reprint Challenges in developing targeted therapy for pancreatic adenocarcinoma
    Devalingam Mahalingam
    Institute of Drug Development, Division of Hematology and Medical Oncology, University of Texas Health Science Centre, San Antonio, Texas 78229, USA
    Expert Opin Ther Targets 12:1389-401. 2008
    ..Research into the molecular pathogenesis of pancreatic cancers has allowed scientists to understand the complex heterogeneous signals associated with them. Targeting these pathways with chemical inhibitors could improve patient outcome...
  22. pmc Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression
    Pramod S Gowda
    Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7762, San Antonio, TX 78229 3900
    Mol Cancer Res 11:1448-61. 2013
    ..Finally, noncompetitive inhibition of androgen receptor, but not competitive inhibition, was effective at limiting the activity of truncated androgen receptor leading to the inhibition of CRPC...
  23. ncbi request reprint A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
    Jordi Rodon
    Authors Affiliations Vall d Hebron Institut d Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania University of Leicester, Leicester, United Kingdom University Hospital of Z├╝rich, Zurich, Switzerland Memorial Sloan Kettering Cancer Center, New York, New York Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas Novartis Institutes for BioMedical Research, Cambridge, Massachusetts and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
    Clin Cancer Res 20:1900-9. 2014
    ....
  24. doi request reprint Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer
    Chun Liang Chen
    Department of Molecular Medicine, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Prostate 73:813-26. 2013
    ..Here we postulate that CTCs expressing genes related to epithelial-mesenchymal transition (EMT) are strong predictors of metastatic prostate cancer...